Clinical Trial Update: Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on periganglionic resiniferatoxin for cancer-induced bone pain; the Phase 1/Phase 2 study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Cancer
• Cancer Pain

Drugs mentioned

• Periganglionic Resiniferatoxin (resiniferatoxin)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Intractable Pain, Palliative Care | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING